Company: Questcor Pharmaceuticals
Liaison(s): Jim Knight, Marilee Moy, Julie Wilson
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on difficult-to-treat and severe autoimmune and inflammatory disorders. The company was formed in 1999 from the merger of Cypros Pharmaceuticals and RiboGene Inc. and has two main products; H.P. Achthar® Gel and Doral®. With current strategies in place, Questcor Pharmaceuticals is growing rapidly and the company posted net revenues of $268 million in 2011. Questcor would like to investigate new market opportunities for various indications within the critical care setting. Additionally, the company would like to evaluate the management of pharmaceuticals within this critical care setting to more fully understand the challenges found in this marketplace. The Questcor TMP team was tasked with performing a market assessment which included the identification of current unmet clinical needs for a number of clinical indications. Ultimately, the team identified high value market opportunities for consideration in Questcor’s strategic market development. To accomplish these goals, the Questcor Pharmaceuticals TMP team carried out extensive secondary research including interviews with Key Opinion Leaders (KOLs) in various specialties. Finally, the team produced a comprehensive case study analysis to aid in corporate planning.
You're Invited to Join KGI for our In-Person Visit Day! April 5 | 9 a.m. - 2 p.m. PST. REGISTER TODAY.